GE HealthCare cuts 2026 profit view; stock drops 13%

What changed for GE HealthCare in Q1 2026

GE HealthCare reported a first-quarter 2026 profit impact and cut its full-year financial outlook, triggering a sharp selloff in its shares. The imaging and medical equipment maker said profitability in the quarter was affected by a pharmaceutical diagnostics supplier issue, which it said has since been resolved. Management also pointed to higher input costs, especially memory chips, oil and freight, and said it assumes these pressures will last through the rest of 2026.

The guidance reset overshadowed otherwise solid demand signals, with investors focusing on whether revenue momentum can translate into profits when costs remain elevated. The update comes as tariffs and global trade dynamics continue to influence sourcing and logistics costs. GE HealthCare’s CEO Peter Arduini framed the outlook change as a cautious step given what the company experienced in the quarter and what it expects to persist.

CEO comments on supplier issues and cost inflation

Arduini said the first-quarter profitability hit was tied to a pharmaceutical diagnostics supplier issue that has now been resolved. He also highlighted “significant increases in memory chips, oil and freight costs” during the quarter, which the company expects to affect the full year.

Arduini said GE HealthCare will take “a prudent approach” by reducing its profit outlook. At the same time, he said the company expects to offset more than half of the inflation impact through pricing and cost actions. The company’s messaging focused on managing the cost base while maintaining its organic revenue growth expectations.

Stock reaction: 13% drop after results

GE HealthCare released its Q1 results ahead of the market open, and the stock fell sharply during the session. Shares on the Nasdaq dropped by over 13% to $19.49 by market close on 29 April, from $18.50 at the prior close on 28 April. Another data point in the reports pegged the move at roughly a 12.8% decline to around $19.75, with an intraday low near $18.75.

The selloff reflected investor disappointment with the profit outlook and margin guidance, not just the quarter’s top-line performance. GE HealthCare’s market capitalisation was cited at around $17.5 billion.

What the company changed in its 2026 guidance

The company cut its full-year adjusted earnings guidance to $1.80 to $1.00 per share, from the prior range of $1.95 to $1.15. It also reduced its adjusted EBIT margin target to 15.4% to 15.7%, down from 15.8% to 16.1%.

GE HealthCare kept its organic revenue growth guidance unchanged at 3% to 4%. In the reports, adjusted EBIT was described as excluding certain items and stripping out interest and taxes.

Q1 numbers investors focused on

Reports said GE HealthCare posted Q1 2026 revenue of $1.13 billion, mildly ahead of estimates in the $1.03 billion to $1.05 billion range. On profitability, one report said adjusted EPS was $1.99, missing a Wall Street consensus of $1.07 by $1.08. Another report cited EPS of $1.85 for the quarter.

While revenue was described as resilient, the market reaction suggested that investors prioritised margin trajectory and the earnings bridge to the reduced full-year outlook. Management commentary on tariffs and cost inflation became the main driver of the day’s repricing.

Tariffs and trade: why costs rose in Q1

On the investor call, Arduini quantified the inflationary impact linked to trade dynamics and inputs. He said the company expects an “approximate $100 million increase in the price of memory chips,” which are critical components across GE HealthCare products. He also anticipated an “increase in oil and freight costs of approximately $100 million,” alongside metals, with the gross impact of these total costs estimated at “approximately $150 million, or $1.43 per share.”

CFO Jay Saccaro said some inflation effects were delayed due to inventory accounting, suggesting heavier pressure could show up later in 2026. He also said earnings took a tariff-related hit of around 16 cents per share in the first quarter, describing it as the company’s “largest quarterly hit this year.” Separate reporting referenced approximately $10 million in tariff-related headwinds.

Geopolitics and shipping costs: Strait of Hormuz disruption

The reports linked rising oil and freight costs to geopolitical developments, citing the US-Israel conflict with Iran and stating that Iran has closed the Strait of Hormuz. The Strait was described as one of the world’s most critical maritime chokepoints, and the closure was cited as a factor making shipping more expensive.

For manufacturers with global supply chains and heavy, high-value shipments, changes in freight rates and transit risk can quickly feed through to cost of goods sold. GE HealthCare’s comments suggest it is baking these conditions into its 2026 planning assumptions.

Key figures at a glance

Market impact: what the reset signals for investors

The immediate market impact was a double hit: an earnings miss (as reported via adjusted EPS) and a clear reduction in profit and margin targets for the year. Investors appeared to discount the stock because the new EPS midpoint of $1.90 sat below an analyst consensus figure of $1.05 cited in the reports. The decision to keep organic revenue growth guidance unchanged at 3% to 4% did not offset concerns that incremental revenue may be absorbed by input costs.

Tariffs remained a central risk factor in the narrative. The reports referenced an unresolved Section 232 national security investigation into medical device imports, which was highlighted as an additional uncertainty for the sector. GE HealthCare also said its 2026 outlook does not assume any benefit from pending tariff claims.

Analysis: why chips, freight and tariffs matter now

GE HealthCare’s cost disclosures provide a numeric frame for what investors are trying to model. The company’s estimate of roughly $100 million higher memory chip costs and roughly $100 million higher oil and freight costs, plus metals, shows how inflation can affect both electronics-heavy imaging systems and global distribution. The cited gross impact of about $150 million, or $1.43 per share, is large enough to influence margin guidance even when revenue holds up.

The company’s plan to offset more than half the inflation impact with pricing and cost actions puts execution under scrutiny. With CFO commentary indicating some impacts were deferred by inventory accounting, investors may watch subsequent quarters for evidence of whether the margin pressure is temporary or extends further into the year. Add tariffs and ongoing trade rules, and the variability increases, particularly when combined with commentary about softness in China in the reports.

What to watch next

Investors are likely to track whether tariff mitigation and pricing actions show up in margins beyond Q1, and whether the resolved pharmaceutical diagnostics supplier issue stays contained. The company’s next updates on costs, tariffs, and any changes tied to trade investigations will matter given management’s assumption that chip and freight inflation persists through 2026. Future quarterly results will also test whether the maintained 3% to 4% organic revenue growth outlook can hold alongside the reduced profit and EBIT margin targets.